# Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease

> **NCT07238985** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tanta University** · enrollment: 50 (estimated)

## Conditions studied

- Fatty Liver

## Interventions

- **OTHER:** Standard therapy
- **DRUG:** Cilostazol

## Key facts

- **NCT ID:** NCT07238985
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2026-11-20
- **Final completion:** 2026-11-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07238985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07238985, "Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07238985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*